AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (260.8 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Commentary | Open Access

RhoA, a novel tumor suppressor or oncogene as a therapeutic target?

Melissa Gilbert-Ross, Adam I. Marcus, Wei Zhou,( )
The Winship Cancer Institute, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA

Peer review under responsibility of Chongqing Medical University.

Show Author Information

Keywords

Tumor suppressor geneRhoAOncogeneCell polarityTherapeutic target

References

1

Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005;21:247–269.
Crossref Google Scholar
2

Avraham H, Weinberg RA. Characterization and expression of the human rhoH12 gene product. Mol Cell Biol. May 1989;9:2058–2066.
Crossref Google Scholar
3

Palomero T, Couronne L, Khiabanian H, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. Feb 2014;46:166–170.
Crossref Google Scholar
4

Yoo HY, Sung MK, Lee SH, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. Nat Genet. Apr 2014;46:371–375.
Crossref Google Scholar
5
Manso R, Sanchez-Beato M, Monsalvo S, et al. The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature. Blood. May 1 2014;123:2893–2894.
Crossref
6
Rohde M, Richter J, Schlesner M, et al. Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols. Genes Chromosomes Cancer. Jul 8 2014.
Crossref
7

Kakiuchi M, Nishizawa T, Ueda H, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. Jun 2014;46:583–587.
Crossref Google Scholar
8
The Cancer Genome Atlas Research N, Analysis Working Group: Dana-Farber Cancer I, Institute for Systems B, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. Jul 23 2014.
9

Wang K, Yuen ST, Xu J, et al. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet. Jun 2014;46:573–582.
Crossref Google Scholar
10
Zhou X, Zheng Y. Cell type-specific signaling function of RhoA GTPase: lessons from mouse gene targeting. J Biol Chem. Dec 20 2013;288:36179–36188.
Crossref
Genes & Diseases
Volume 2 Issue 1,
January 2015
Pages 2-3
DOI: 10.1016/j.gendis.2014.10.001
Cite this article:
Gilbert-Ross M, Marcus AI, Zhou W. RhoA, a novel tumor suppressor or oncogene as a therapeutic target?. Genes & Diseases, 2015, 2(1): 2-3. https://doi.org/10.1016/j.gendis.2014.10.001

256

Views

1

Downloads

5

Crossref

N/A

Web of Science

6

Scopus

0

CSCD

Altmetrics
Received: 04 October 2014
Published: 01 November 2014
© 2014, Chongqing Medical University.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Return